SCHEMBL3223085

SCHEMBL3223085

CC(=O)OCCN(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.69
ALDH1A1 P00352 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.51
MAOB P27338 1/20 0.47
HDAC3 O15379 2/20 0.46
HDAC1 Q13547 2/20 0.46
HDAC2 Q92769 2/20 0.46
HDAC8 Q9BY41 2/20 0.46
NCOR2 Q9Y618 2/20 0.46
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
SCN1A P35498 1/20 0.46
SCN2A Q99250 1/20 0.46
SCN3A Q9NY46 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CYP3A4 P08684 1/20 0.45
RORC P51449 1/20 0.44
CHRM2 P08172 2/20 0.44
CHRM1 P11229 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12671106 0.97 TSHR (0.65) TSHRALDH1A1SMN1; SMN2MAOBLMNA
SCHEMBL1665202 0.85 SMN1; SMN2 (0.70) TSHRALDH1A1SMN1; SMN2L3MBTL1POLB
SCHEMBL7202690 0.84 TSHR (0.53) TSHRALDH1A1SMN1; SMN2MAOBHDAC3
SCHEMBL4176309 0.83 TSHR (0.52) TSHRALDH1A1SMN1; SMN2MAOBHDAC3
SCHEMBL28454697 0.83 TSHR (0.53) TSHRALDH1A1SMN1; SMN2MAOBHDAC3
SCHEMBL27820221 0.83 TSHR (0.53) TSHRALDH1A1SMN1; SMN2MAOBLMNA
SCHEMBL9704306 0.83 MAOB (0.59) TSHRALDH1A1MAOBCYP2D6SCN1A
SCHEMBL14822453 0.82 TSHR (0.52) TSHRALDH1A1SMN1; SMN2MAOBLMNA
SCHEMBL9652432 0.82 TSHR (0.51) TSHRALDH1A1SMN1; SMN2CHRM1NPC1
SCHEMBL23871091 0.81 TSHR (0.50) TSHRALDH1A1SMN1; SMN2HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338490-B2 Composition for repelling and deterring vermin NOVARTIS AG (CH) 2012-12-25 US claimed
EP-2094079-B1 COMPOSITION FOR REPELLING AND DETERRING VERMIN NOVARTIS AG (CH) 2012-11-14 EP claimed
US-20100063090-A1 Composition for Repelling and Deterring Vermin NOVARTIS AG (CH) 2010-03-11 US claimed
EP-2094079-A1 COMPOSITION FOR REPELLING AND DETERRING VERMIN Novartis Ag (CH) 2009-09-02 EP claimed
EP-1264212-B1 ELEMENTS FOR FORMING PRINT-OUT IMAGES DU PONT (US) 2009-02-18 EP claimed
WO-2008062006-A1 COMPOSITION FOR REPELLING AND DETERRING VERMIN NOVARTIS AG (CH) 2008-05-29 WO claimed
US-6869755-B2 Elements for forming print-out images E. I. DU PONT DE NEMOURS AND COMPANY (US) 2005-03-22 US claimed
EP-1264212-A2 ELEMENTS FOR FORMING PRINT-OUT IMAGES E. I. du Pont de Nemours and Company (US) 2002-12-11 EP claimed
US-20020146649-A1 Elements for forming print-out images E. I. DU PONT DE NEMOURS AND COMPANY 2002-10-10 US claimed
WO-2001067175-A2 ELEMENTS FOR FORMING PRINT-OUT IMAGES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2001-09-13 WO claimed
US-20240294523-A1 HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2024-09-05 US disclosed
US-8940782-B2 Composition for repelling and deterring vermin NOVARTIS AG (CH) 2015-01-27 US disclosed
US-8940782-B2 Composition for repelling and deterring vermin NOVARTIS AG (CH) 2015-01-27 US disclosed
US-8940782-B2 Composition for repelling and deterring vermin NOVARTIS AG (CH) 2015-01-27 US disclosed
US-20130143924-A1 COMPOSITION FOR REPELLING AND DETERRING VERMIN ELANCO TIERGESUNDHEIT AG (CH) 2013-06-06 US disclosed
EP-1264212-A2 ELEMENTS FOR FORMING PRINT-OUT IMAGES E. I. du Pont de Nemours and Company (US) 2002-12-11 EP disclosed
US-20020146649-A1 Elements for forming print-out images E. I. DU PONT DE NEMOURS AND COMPANY 2002-10-10 US disclosed
WO-2001067175-A2 ELEMENTS FOR FORMING PRINT-OUT IMAGES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2001-09-13 WO disclosed
US-4078934-A Photosensitive, image-forming composition containing a leuco 2,3-disubstituted-1-indanone and a photooxidant E. I. DU PONT DE NEMOURS AND COMPANY (US) 1978-03-14 US disclosed
US-3992450-A PHOTOSENSITIVE COMPOSITIONS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294523-A1 HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF RIPK1, RIPK4, RIPK3 TSHR 4717/4885ALDH1A1 4023/4885SMN1; SMN2 3447/4885
US-20100063090-A1 Composition for Repelling and Deterring Vermin AAAS, SERPINC1, FABP1 TSHR 4189/4885ALDH1A1 86/4885SMN1; SMN2 1872/4885
US-20130143924-A1 COMPOSITION FOR REPELLING AND DETERRING VERMIN ACHE, PNMT, AAAS TSHR 4249/4885ALDH1A1 175/4885SMN1; SMN2 2131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.